- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
First Trust Nasdaq Pharmaceuticals ETF(FTXH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for FTXH
11/20/2026: FTXH (2-star) has a low Upturn Star Rating. Not recommended to BUY.
First Trust Nasdaq Pharmaceuticals ETF (FTXH) provides targeted exposure to large and liquid U.S. pharmaceutical companies through a rules-based smart-beta index that screens for value, growth, low volatility, and liquidity. Its main strengths lie in its systematic multi-factor methodology and liquidity-focused design, which help mitigate single-stock concentration risks. It serves primarily as a tactical sector allocation tool or a specialized core-satellite holding for healthcare exposure. Key risks include a relatively high expense ratio of 0.60% and industry-specific vulnerabilities such as drug pricing regulations and patent expirations. The fund is well-suited for growth- or value-conscious investors looking for systematic pharmaceutical exposure while monitoring regulatory and sector performance drivers.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Pharmaceutical sectors generally blend stable cash flows with moderate growth rather than aggressive expansion. |
| Momentum investor | Strong fit while signal remains positive | The index explicitly screens for positive price momentum factors during its quarterly evaluations. |
| Value investor | Strong fit | The smart-beta design incorporates cash-flow-to-price metrics to tilt allocations toward attractive valuations. |
| Dividend/Income investor | Mixed fit | While many pharma holdings pay dividends, FTXH prioritizes multi-factor scoring over high-yield optimization. |
| Low-risk investor | Mixed fit | Sector concentration introduces industry-specific regulatory and clinical trial risks despite low-volatility screening. |
Investor Profile
Ideal Investor Profile
Investors seeking targeted, factor-screened exposure to the U.S. pharmaceutical industry who prefer a rules-based alternative to traditional market-cap weighting.
Suitability
Best suited for long-term strategic asset allocation or tactical sector rotation within a diversified investment portfolio.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | Medium | Healthcare stocks offer defensive characteristics, though individual stock volatility is moderated via factor screening. |
| Market risk | Medium / high | Broader macroeconomic shocks and equity market drawdowns directly impact fund performance. |
| Concentration | High | The fund restricts exposure to a focused basket of approximately 30 to 50 pharmaceutical firms. |
| Tracking/expense | Medium | An expense ratio of 0.60% is somewhat elevated compared to broader health sector index funds. |
| Liquidity | Low | Underlying holdings are selected for high daily trading volumes, supporting efficient creation and redemption. |
| Business/sector quality | Medium / high | Constituents are established domestic pharmaceutical leaders with robust balance sheets and cash flows. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
Historical volatility is kept moderate due to the inclusion of low-volatility factor filters, though sector-specific shocks can induce short-term price swings.
Market Risk
Subject to systematic equity risks as well as regulatory, legal, and clinical trial outcomes unique to pharmaceutical companies.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Industry | U.S. Pharmaceuticals & Biotechnology Equity Securities | 96 | Provides targeted multi-factor exposure to the domestic pharmaceutical industry. |
| Cash/collateral | Cash and Cash Equivalents | 4 | Maintains a minor liquidity buffer for daily administrative efficiency and operational distributions. |
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit 63.77% | Avg. Invested days 100 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

